Carmichael Hill & Associates, Inc. Kiniksa Pharmaceuticals, Ltd. Transaction History

Carmichael Hill & Associates, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 24, 2024	SELL	$17.63 - $21.74 $4,372 - $5,391	-248 Reduced 31.79%	532 $10,000
Q3 2023 Oct 30, 2023	BUY	$13.62 - $20.2 $2,397 - $3,555	176 Added 29.14%	780 $13,000
Q2 2023 Aug 04, 2023	BUY	$10.44 - $16.48 $1,586 - $2,504	152 Added 33.63%	604 $8,000
Q1 2023 Apr 05, 2023	BUY	$10.7 - $15.79 $1,925 - $2,842	180 Added 66.18%	452 $4,000
Q3 2022 Nov 10, 2022	BUY	$9.76 - $13.41 $234 - $321	24 Added 9.68%	272 $3,000
Q1 2022 May 16, 2022	BUY	$9.3 - $12.37 $2,306 - $3,067	248 New	248 $2,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $751M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Carmichael Hill & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Carmichael Hill & Associates, Inc. with notifications on news.